Clinical Trials Directory

Trials / Completed

CompletedNCT03000231

Circadian Function and Cardio-metabolic Risk in Adrenal Insufficiency

Circadian Function and Cardio-metabolic Risk in Adrenal Insufficiency: a Case Control Study

Status
Completed
Phase
Study type
Observational
Enrollment
86 (actual)
Sponsor
University of Chicago · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to compare cardio-metabolic risk, glucose tolerance, and night time blood pressure between healthy control subjects and patients with adrenal insufficiency. No intervention will be administered and the study is observational only.

Detailed description

We propose to use a case control design to test the main hypothesis that as compared to healthy control subjects matched for sex, age, adiposity and race/ethnicity, patients with adrenal insufficiency, whether primary or secondary, have disturbances of the circadian system that are associated with high day to day variability of sleep time as well as elevated markers of cardio-metabolic risk, including abnormal oral glucose tolerance and reduced nocturnal blood pressure dipping. A secondary hypothesis of the study is that adrenal insufficiency patients on a replacement regimen (as part of their standard of care ongoing treatment) that results in daytime cortisol profiles approximating the normal diurnal variation will have better cardio-metabolic function than adrenal insufficiency patients who have grossly abnormal cortisol profiles.

Conditions

Timeline

Start date
2015-10-01
Primary completion
2023-12-01
Completion
2023-12-01
First posted
2016-12-22
Last updated
2024-02-28

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03000231. Inclusion in this directory is not an endorsement.